International Journal of Nanomedicine (May 2023)
Lipid Nanocarrier-Based Drug Delivery Systems: Therapeutic Advances in the Treatment of Lung Cancer
Abstract
So-Jung Kim,1,* Nidhi Puranik,2,* Dhananjay Yadav,3,* Jun-O Jin,1 Peter CW Lee4 1Department of Microbiology, University of Ulsan College of Medicine, Seoul, 05505, South Korea; 2Department of Biochemistry & Genetics, Barkatullah University, Bhopal, Madhya Pradesh, 462026, India; 3Department of Life Science, Yeungnam University, Gyeongsan, 38541, Korea; 4Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, ASAN Medical Center, Seoul, 05505, South Korea*These authors contributed equally to this workCorrespondence: Peter CW Lee, Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, ASAN Medical Center, Seoul, 05505, Korea, Email [email protected] Jun-O Jin, Department of Microbiology, University of Ulsan College of Medicine, Seoul, 05505, Korea, Email [email protected]: Although various treatments are currently being developed, lung cancer still has a very high mortality rate. Moreover, while various strategies for the diagnosis and treatment of lung cancer are being used in clinical settings, in many cases, lung cancer does not respond to treatment and presents reducing survival rates. Cancer nanotechnology, also known as nanotechnology in cancer, is a relatively new topic of study that brings together scientists from a variety of fields, including chemistry, biology, engineering, and medicine. The use of lipid-based nanocarriers to aid drug distribution has already had a significant impact in several scientific fields. Lipid-based nanocarriers have been demonstrated to help stabilize therapeutic compounds, overcome barriers to cellular and tissue absorption, and improve in vivo drug delivery to specific target areas. For this reason, lipid-based nanocarriers are being actively researched and used for lung cancer treatment and vaccine development. This review discusses the improvements in drug delivery achieved with lipid-based nanocarriers, the obstacles that still exist with in vivo applications, and the current clinical and experimental applications of lipid-based nanocarriers in lung cancer treatment and management.Keywords: lung cancer, lipid-based nanocarriers, liposome, drug delivery system
